News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
The company received gross proceeds of approximately US$1.7 million and net proceeds,
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Development services for gene and cell therapies is planned to begin first in 2025
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Subscribe To Our Newsletter & Stay Updated
